A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma

Al B Benson 3rd, Zev A Wainberg, J Randolph Hecht, Dmitry Vyushkov, Hua Dong, Johanna Bendell, Fred Kudrik, Al B Benson 3rd, Zev A Wainberg, J Randolph Hecht, Dmitry Vyushkov, Hua Dong, Johanna Bendell, Fred Kudrik

Abstract

Lessons learned: The safety profile in the gemcitabine/simtuzumab group was similar to that in the gemcitabine/placebo group.The addition of simtuzumab to gemcitabine does not improve clinical outcomes in patients with metastatic pancreatic adenocarcinoma ABSTRACT: Background.The humanized IgG4 monoclonal antibody simtuzumab inhibits the extracellular matrix-remodeling enzyme lysyl oxidase-like 2 maintaining pathological stroma in tumors.

Methods: Adult patients with metastatic pancreatic adenocarcinoma (mPaCa) were randomly assigned to receive intravenous gemcitabine, 1,000 mg/m2, in combination with 200 or 700 mg simtuzumab or placebo. Primary endpoint was progression-free survival (PFS), secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.

Results: Of 240 patients, 80 were randomly assigned to gemcitabine/simtuzumab 700 mg, 79 to gemcitabine/simtuzumab 200 mg, and 81 to gemcitabine/placebo. After a median follow-up of 3.0, 1.9, and 3.4 months for gemcitabine/simtuzumab 700 mg, gemcitabine/simtuzumab 200 mg, and gemcitabine/placebo, respectively, the median PFS was 3.7 months (adjusted hazard ratio [HR], 95% confidence interval [CI], p value vs placebo: 1.09 [0.74-1.61]; p = .73), 3.5 months (1.13 [0.76-1.66], p = .61]), and 3.7 months, respectively. Median OS was 7.6 months (0.83 [0.57-1.22]; p = .28), 5.9 months (1.07 [0.73-1.55]; p = .69), and 5.7 months, respectively. ORRs were 13.9%, 14.5%, and 23.5%, respectively. Simtuzumab was well tolerated.

Conclusion: The addition of simtuzumab to gemcitabine did not improve clinical outcomes in patients with mPaCa. The Oncologist 2017;22:241-e7.

Trial registration: ClinicalTrials.gov NCT01472198.

© AlphaMed Press; the data published online to support this summary is the property of the authors.

Figures

Figure 1.
Figure 1.
Stratified Kaplan–Meier plot of progression‐free survival by independent review committee assessment (FAS population). Abbreviations: CI, confidence interval; FAS, full analysis set (all patients randomized and treated with 1 dose of study drug); HR, hazard ratio (numbers in brackets are 95% CIs); PFS, progression‐free survival; SIM, simtuzumab.
Figure 2.
Figure 2.
Stratified Kaplan–Meier plot of overall survival (FAS population). Abbreviations: CI, confidence interval; FAS, full analysis set (all patients randomized and treated with 1 dose of study drug); HR, hazard ratio (numbers in brackets are 95% CIs); OS, overall survival; SIM, simtuzumab.

References

    1. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–386.
    1. Pancreatic Cancer Facts . 2015. Pancreatic Cancer Action Network. Available at . Accessed May 12, 2016.
    1. Chu GC, Kimmelman AC, Hezel AF et al. Stromal biology of pancreatic cancer. J Cell Biochem 2007;101:887–907.
    1. Farrow B, Albo D, Berger DH. The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res 2008;149:319–328.
    1. National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology. Pancreatic adenocarcinoma. 2016. Available at . Accessed May 12, 2016.
    1. Barry‐Hamilton V, Spangler R, Marshall D et al. Allosteric inhibition of lysyl oxidase‐like‐2 impedes the development of a pathologic microenvironment. Nat Med 2010;16:1009–1017.
    1. Fong SF, Dietzsch E, Fong KS et al. Lysyl oxidase‐like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors. Genes Chromosomes Cancer 2007;46:644–‐655.
    1. Benson A, Bendell J, Wainberg Z et al. A phase 2 randomized, double‐blind, placebo controlled study of simtuzumab or placebo in combination with gemcitabine for the first line treatment of pancreatic adenocarcinoma. Ann Oncol 2014;25;iv210–iv253.
    1. Zaffryar‐Eilot S, Marshall D, Voloshin T et al. Lysyl oxidase‐like‐2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours. Carcinogenesis 2013;34:2370–2379.
    1. Payne SL, Hendrix MJ, Kirschmann DA. Paradoxical roles for lysyl oxidases in cancer—a prospect. J Cell Biochem 2007;101:1338–1354.
    1. Rodriguez HM, Vaysberg M, Mikels A et al. Modulation of lysyl oxidase‐like 2 enzymatic activity by an allosteric antibody inhibitor. J Biol Chem 2010;285:20964–20974.
    1. Van Bergen T, Marshall D, Van de Veire S et al. The role of LOX and LOXL2 in scar formation after glaucoma surgery. Invest Ophthalmol Vis Sci 2013;54:5788–5796.
    1. Peng L, Ran YL, Hu H et al. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. Carcinogenesis 2009;30:1660–1669.
    1. LoRusso P, Hecht J, Thai D et al. Phase I and IIa studies of simtuzumab alone and in combination with FOLFIRI in patients with advanced solid tumors. J Clin Oncol 2014;32:abstract 554.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever